一例转移性MET外显子14跳过非小细胞肺癌癌症且表现不佳的高症状患者对替普替尼的显著反应:病例报告

IF 0.2 Q4 ONCOLOGY
Sebastian Kraus
{"title":"一例转移性MET外显子14跳过非小细胞肺癌癌症且表现不佳的高症状患者对替普替尼的显著反应:病例报告","authors":"Sebastian Kraus","doi":"10.1016/j.cpccr.2023.100230","DOIUrl":null,"url":null,"abstract":"<div><p>Targeted therapies are recommended for treatment of patients with non-small cell lung cancer (NSCLC) with actionable driver mutations, including those with poor performance status, who otherwise have limited treatment options. However, clinical trial evidence in patients with poor performance status is often sparse, especially for newer drug classes. Tepotinib, an oral, once-daily MET inhibitor, was recently approved for the treatment of advanced/metastatic NSCLC with <em>MET</em> exon 14 (<em>MET</em>ex14) skipping based on the durable clinical activity observed in the Phase II VISION trial. We report an excellent response to tepotinib in a patient with metastatic NSCLC with <em>MET</em>ex14 skipping, which was achieved despite a poor baseline Eastern Cooperative Oncology Group performance status (ECOG PS) of 3, substantial symptom burden, and prior intolerance to chemotherapy. The patient attained a rapid, near-complete radiographic response, evident from the first tumor assessment at 2 months, which was maintained for &gt;8 months (ongoing at the time of writing) and correlated with the alleviation of all disease-related symptoms and improvement in ECOG PS to 0. Tepotinib was well tolerated despite the poor clinical condition and prior intolerance to chemotherapy. This case report provides real-world evidence for the clinical effectiveness of tepotinib and indicates that a dramatic response can be attained without clinically significant adverse events, even in a patient who would typically be ineligible for clinical trials due to poor ECOG PS.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dramatic response to tepotinib in a highly symptomatic patient with metastatic MET exon 14 skipping non-small cell lung cancer and poor performance status: A case report\",\"authors\":\"Sebastian Kraus\",\"doi\":\"10.1016/j.cpccr.2023.100230\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Targeted therapies are recommended for treatment of patients with non-small cell lung cancer (NSCLC) with actionable driver mutations, including those with poor performance status, who otherwise have limited treatment options. However, clinical trial evidence in patients with poor performance status is often sparse, especially for newer drug classes. Tepotinib, an oral, once-daily MET inhibitor, was recently approved for the treatment of advanced/metastatic NSCLC with <em>MET</em> exon 14 (<em>MET</em>ex14) skipping based on the durable clinical activity observed in the Phase II VISION trial. We report an excellent response to tepotinib in a patient with metastatic NSCLC with <em>MET</em>ex14 skipping, which was achieved despite a poor baseline Eastern Cooperative Oncology Group performance status (ECOG PS) of 3, substantial symptom burden, and prior intolerance to chemotherapy. The patient attained a rapid, near-complete radiographic response, evident from the first tumor assessment at 2 months, which was maintained for &gt;8 months (ongoing at the time of writing) and correlated with the alleviation of all disease-related symptoms and improvement in ECOG PS to 0. Tepotinib was well tolerated despite the poor clinical condition and prior intolerance to chemotherapy. This case report provides real-world evidence for the clinical effectiveness of tepotinib and indicates that a dramatic response can be attained without clinically significant adverse events, even in a patient who would typically be ineligible for clinical trials due to poor ECOG PS.</p></div>\",\"PeriodicalId\":72741,\"journal\":{\"name\":\"Current problems in cancer. Case reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current problems in cancer. Case reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666621923000157\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current problems in cancer. Case reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666621923000157","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

推荐靶向治疗具有可操作驱动突变的非小细胞癌症(NSCLC)患者,包括那些表现不佳的患者,否则他们的治疗选择有限。然而,在表现不佳的患者中,临床试验证据往往很少,尤其是对于较新的药物类别。基于在II期VISION试验中观察到的持久临床活性,替泊替尼是一种口服的、每天一次的MET抑制剂,最近被批准用于治疗晚期/转移性NSCLC,MET外显子14(METex14)跳过。我们报告了一名METex14跳过的转移性NSCLC患者对替波替尼的良好反应,尽管东部肿瘤协作组基线表现不佳(ECOG PS)为3,症状负担严重,且既往对化疗不耐受,但还是取得了良好的疗效。患者获得了快速的、接近完全的放射学反应,这从2个月时的第一次肿瘤评估中是明显的,其维持>;8个月(在撰写本文时正在进行),并与所有疾病相关症状的缓解和ECOG PS改善至0相关。尽管特波替尼的临床状况不佳,且之前对化疗不耐受,但其耐受性良好。该病例报告为替波替尼的临床有效性提供了真实世界的证据,并表明即使在因ECOG PS不佳而通常不符合临床试验条件的患者中,也可以在没有临床重大不良事件的情况下获得显著的反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Dramatic response to tepotinib in a highly symptomatic patient with metastatic MET exon 14 skipping non-small cell lung cancer and poor performance status: A case report

Targeted therapies are recommended for treatment of patients with non-small cell lung cancer (NSCLC) with actionable driver mutations, including those with poor performance status, who otherwise have limited treatment options. However, clinical trial evidence in patients with poor performance status is often sparse, especially for newer drug classes. Tepotinib, an oral, once-daily MET inhibitor, was recently approved for the treatment of advanced/metastatic NSCLC with MET exon 14 (METex14) skipping based on the durable clinical activity observed in the Phase II VISION trial. We report an excellent response to tepotinib in a patient with metastatic NSCLC with METex14 skipping, which was achieved despite a poor baseline Eastern Cooperative Oncology Group performance status (ECOG PS) of 3, substantial symptom burden, and prior intolerance to chemotherapy. The patient attained a rapid, near-complete radiographic response, evident from the first tumor assessment at 2 months, which was maintained for >8 months (ongoing at the time of writing) and correlated with the alleviation of all disease-related symptoms and improvement in ECOG PS to 0. Tepotinib was well tolerated despite the poor clinical condition and prior intolerance to chemotherapy. This case report provides real-world evidence for the clinical effectiveness of tepotinib and indicates that a dramatic response can be attained without clinically significant adverse events, even in a patient who would typically be ineligible for clinical trials due to poor ECOG PS.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.40
自引率
0.00%
发文量
0
审稿时长
96 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信